One pill may tame both itchy skin and stubborn liver disease
NCT ID NCT07678645
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether upadacitinib, a drug already approved for eczema, can help people who have both atopic dermatitis (a type of eczema) with moderate to severe itching and a hard-to-treat autoimmune liver disease called cholangitis. The drug works by blocking a pathway involved in both itching and liver inflammation. Researchers will measure changes in itch severity, liver enzyme levels, and liver stiffness over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib
What this could lead to
If it works, this could offer a new treatment option for people with both atopic dermatitis and hard-to-treat autoimmune liver disease, potentially easing itching and slowing liver damage.
What could go wrong
This is a small, early-phase study with no placebo group, so results may not be conclusive. Upadacitinib can have side effects like infections or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RenJi Hospital
Shanghai, Shanghai Municipality, 200001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••